Brands should ask about GHK-Cu concentration, pH range, ingredient compatibility, preservative system, color stability, packaging protection, and storage conditions
A deficiency in vitamin B12 can lead to a variety of health issues, including anaemia and neurological problems
Brand-name Wegovy carries a retail price that makes it inaccessible for many people without insurance coverage
Mechanism of Action Tirzepatide: Dual incretin (GIP + GLP-1) enhanced metabolic impact Wegovy: GLP-1 receptor agonist now with higher receptor engagement Weight Loss Outcomes Tirzepatide: ~22% weight reduction in trials Wegovy 7.2 mg: ~2021% weight reduction The efficacy gap is narrowing significantly Cardiometabolic Profile Wegovy: Strong, established cardiovascular outcome data Tirzepatide: Superior glycemic control and insulin sensitivity Safety & Tolerability Both therapies show dose-dependent GI side effects Overall safety profiles remain comparable The Big Picture We are witnessing a shift from: Single-hormone optimization (high-dose semaglutide) to Multi-hormone targeting (tirzepatide) Conclusion While Wegovy is rapidly closing the efficacy gap with dose escalation, Tirzepatide continues to lead as a next-generation metabolic therapy
Stenosis is more common in people aged 60 or older and in those who are overweight
